InvestorsHub Logo
Followers 3
Posts 282
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Wednesday, 04/24/2024 11:23:31 AM

Wednesday, April 24, 2024 11:23:31 AM

Post# of 608
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RIGL News